Rubric Capital Management LP Raises Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Rubric Capital Management LP lifted its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 76.5% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 3,736,802 shares of the company’s stock after acquiring an additional 1,619,748 shares during the period. Rubric Capital Management LP owned approximately 1.00% of GoodRx worth $29,147,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Canada Pension Plan Investment Board grew its stake in shares of GoodRx by 5.9% during the second quarter. Canada Pension Plan Investment Board now owns 166,142 shares of the company’s stock worth $1,296,000 after acquiring an additional 9,200 shares during the last quarter. XTX Topco Ltd boosted its position in GoodRx by 42.4% in the second quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock valued at $231,000 after buying an additional 8,801 shares during the last quarter. Plato Investment Management Ltd purchased a new stake in GoodRx in the second quarter valued at approximately $43,000. Cornercap Investment Counsel Inc. boosted its position in GoodRx by 1.7% in the second quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock valued at $587,000 after buying an additional 1,266 shares during the last quarter. Finally, American Century Companies Inc. purchased a new stake in GoodRx in the second quarter valued at approximately $18,183,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Stock Performance

NASDAQ GDRX opened at $6.91 on Friday. The stock has a market cap of $2.59 billion, a PE ratio of -691.00, a P/E/G ratio of 3.55 and a beta of 1.38. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.96. GoodRx Holdings, Inc. has a twelve month low of $4.14 and a twelve month high of $9.26. The stock has a fifty day simple moving average of $7.97 and a 200-day simple moving average of $7.59.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $200.60 million for the quarter, compared to analysts’ expectations of $200.47 million. GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.02 earnings per share. Equities analysts anticipate that GoodRx Holdings, Inc. will post 0.15 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.17% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Citigroup dropped their target price on GoodRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 target price on shares of GoodRx in a research note on Friday, August 16th. Raymond James raised GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price for the company in a research note on Friday, August 9th. UBS Group reduced their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research note on Friday, August 9th. Finally, Morgan Stanley upped their target price on GoodRx from $7.00 to $9.50 and gave the stock an “equal weight” rating in a research note on Monday, June 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.36.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.